Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody Response

Human adenoviruses (AdV) are mostly associated with minimal pathology. However, more severe respiratory tract infections and acute respiratory diseases, most often caused by AdV-4 and AdV-7, have been reported. The only licensed vaccine in the United States, live oral AdV-4 and AdV-7 vaccine, is indicated for use in the military, nearly exclusively in recruit populations. The excellent safety profile and prominent antibody response of the vaccine is well established by placebo-controlled clinical trials, while, long-term immunity of vaccination has not been studied. Serum samples collected over 6 years from subjects co-administered live oral AdV-4 and AdV-7 vaccine in 2011 were evaluated to determine the duration of the antibody response. Group geometric mean titers (GMT) at 6 years post vaccination compared to previous years evaluated were not significantly different for either AdV-4 or AdV-7 vaccine components. There were no subjects that demonstrated waning neutralization antibody (NAb) titers against AdV-4 and less than 5% of subjects against AdV-7. Interestingly, there were subjects that had a four-fold increase in NAb titers against either AdV-4 or AdV-7, at various time points post vaccination, suggesting either homotypic or heterotypic re-exposure. This investigation provided strong evidence that the live oral AdV-4 and AdV-7 vaccine induced long-term immunity to protect from AdV-4 and AdV-7 infections.

[1]  J. Choi,et al.  Ongoing outbreak of human adenovirus-associated acute respiratory illness in the Republic of Korea military, 2013 to 2018 , 2019, The Korean journal of internal medicine.

[2]  K. St. George,et al.  Emergence and re-emergence of respiratory adenoviruses in the United States. , 2019, Current opinion in virology.

[3]  Deirdre Brady,et al.  Adenovirus Type 4 Respiratory Infections among Civilian Adults, Northeastern United States, 2011–2015 , 2018, Emerging infectious diseases.

[4]  K. St. George,et al.  Adenovirus Type 4 Respiratory Infections among Civilian Adults, Northeastern United States, 2011–2015 , 2018, Emerging infectious diseases.

[5]  R. Jarman,et al.  Adenovirus type 4 respiratory infections with a concurrent outbreak of coxsackievirus A21 among United States Army Basic Trainees, a retrospective viral etiology study using next‐generation sequencing , 2017, Journal of medical virology.

[6]  S. Gu,et al.  Febrile Respiratory Illness Associated with Human Adenovirus Type 55 in South Korea Military, 2014–2016 , 2017, Emerging infectious diseases.

[7]  J. Gaydos,et al.  Acute Respiratory Disease in US Army Trainees 3 Years after Reintroduction of Adenovirus Vaccine , 2017, Emerging infectious diseases.

[8]  J. Lynch,et al.  Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention , 2016, Seminars in Respiratory and Critical Care Medicine.

[9]  M. Ison,et al.  Severe Infections with Human Adenovirus 7d in 2 Adults in Family, Illinois, USA, 2014 , 2016, Emerging infectious diseases.

[10]  Christopher L. Perdue,et al.  A Brief Description of the Operation of the DoD Serum Repository. , 2015, Military medicine.

[11]  J. Pavlin,et al.  Ethics, Human Use, and the Department of Defense Serum Repository. , 2015, Military medicine.

[12]  D. Metzgar,et al.  Molecular Epidemiology of Adenovirus Type 21 Respiratory Strains Isolated From US Military Trainees (1996-2014). , 2015, The Journal of infectious diseases.

[13]  D. Seto,et al.  Computational analysis of four human adenovirus type 4 genomes reveals molecular evolution through two interspecies recombination events. , 2013, Virology.

[14]  J. D. de Jong,et al.  Molecular and serological characterization of species B2 adenovirus strains isolated from children hospitalized with acute respiratory disease in Buenos Aires, Argentina. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  K. Russell,et al.  A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. military recruits. , 2013, Vaccine.

[16]  C. Hoke,et al.  History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. , 2013, Vaccine.

[17]  A. Hawksworth,et al.  Initial assessment of impact of adenovirus type 4 and type 7 vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012. , 2012, MSMR.

[18]  K. Russell,et al.  Serosurvey of bacterial and viral respiratory pathogens among deployed U.S. service members. , 2011, American journal of preventive medicine.

[19]  D. Metzgar,et al.  Genome sequences of Human Adenovirus 14 isolates from mild respiratory cases and a fatal pneumonia, isolated during 2006-2007 epidemics in North America , 2010, Respiratory research.

[20]  D. Metzgar,et al.  A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. , 2008, Vaccine.

[21]  Jose L. Sanchez,et al.  Emergence of adenovirus type 14 in US military recruits--a new challenge. , 2007, The Journal of infectious diseases.

[22]  J. Dawson,et al.  Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  David J. Ecker,et al.  Transmission Dynamics and Prospective Environmental Sampling of Adenovirus in a Military Recruit Setting , 2006, The Journal of infectious diseases.

[24]  D. Vaughn,et al.  Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. Kelley,et al.  Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. , 1998, The Journal of infectious diseases.

[26]  C. Gaydos,et al.  Adenovirus vaccines in the U.S. military. , 1995, Military medicine.

[27]  D. Schnurr,et al.  Quantitative colorimetric microneutralization assay for characterization of adenoviruses , 1994, Journal of clinical microbiology.

[28]  K. Sakae,et al.  Adenovirus Infection and Specific Secretory IgA Responses in the Intestine of Infants , 1992, Microbiology and immunology.

[29]  N. del Grosso,et al.  Neutralizing antibodies against 33 human adenoviruses in normal children in Rome , 1982, Journal of Hygiene.

[30]  W. C. Gamble,et al.  Reference equine antisera to 33 human adenovirus types: homologous and heterologous titers , 1975, Journal of clinical microbiology.

[31]  R. M. Scott,et al.  Enteric Immunization with Live Adenovirus Type 21 Vaccine II. Systemic and Local Immune Responses Following Immunization , 1972, Infection and immunity.

[32]  W. Altemeier,et al.  Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses. , 1970, The Journal of infectious diseases.

[33]  J. Bellanti,et al.  Immunoglobulin responses in serum and nasal secretions after natural adenovirus infections. , 1969, Journal of immunology.

[34]  J. P. van der Veen,et al.  Vaccination with live type 4 adenovirus: evaluation of antibody response and protective efficacy , 1968, Epidemiology and Infection.

[35]  J. Fox,et al.  Standardization and certification of reference antigens and antisera for 30 human adenovirus serotypes. , 1967, American journal of epidemiology.

[36]  R. R. Rafajko.  PRODUCTION AND STANDARDIZATION OF ADENOVIRUS TYPES 1 TO 18 REFERENCE ANTISERA. , 1964, American journal of hygiene.

[37]  A. Prins,et al.  Studies of the significance of the recall phenomenon in the antibody response to adenovirus vaccine and infection. , 1960, Journal of immunology.

[38]  M. Hilleman,et al.  Vaccination against acute respiratory illness of adenovirus (RI-APC-ARD) etiology. , 1957, American journal of public health and the nation's health.